Inventiva Awaits Phase 3 Nativ3 Data For Lanifibranor

With topline results from the Phase 3 NATiV3 trial expected in Q4 2026, Inventiva is already absorbing the commercial and operational costs of preparing lanifibranor for a potential market entry in a disease area that currently has no approved oral therapies for MASH. For manufacturing and regulatory leads tracking this program, the data readout will trigger immediate decisions around process validation, dossier submission timelines, and supply-chain buildout.

Inventiva's first-half 2026 financials reflect that pre-launch posture directly. R&D expenses reached €46.2 million for the six months ended June 30, 2026, a 3.0% increase over the €44.9 million recorded in H1 2025, driven entirely by lanifibranor's clinical development following the discontinuation of preclinical activities in mid-2025. Marketing and business development spend rose sharply to €2.6 million from €0.7 million in the prior-year period, with the company attributing the increase to personnel and expenses tied to commercial readiness contingent on approval. G&A expenses climbed to €22.2 million from €14.7 million, reflecting €4.7 million in additional personnel costs, share-based compensation, and consulting fees linked to the same commercial preparation effort.

The company recorded no revenues in H1 2026, compared to €4.5 million in H1 2025, which had been attributable to the 2022 license agreement with Chia Tai Tianqing Pharmaceutical Group. Net loss for the period narrowed substantially to €69.5 million from €175.9 million in H1 2025, though the prior-year figure was heavily distorted by a €113.2 million net financial loss tied to warrant restructuring and convertible instrument accounting under IFRS fair value rules. Net financial income in H1 2026 was €0.9 million, reflecting non-cash movements on instruments connected to the European Investment Bank warrant restructuring and senior secured convertible bonds issued in June 2026 with funds managed by BlackRock and Claret Capital Partners.

Inventiva held €166.1 million in cash and cash equivalents plus €67.8 million in short-term deposits as of June 30, 2026. Cash runway guidance, last updated July 30, 2026, remains unchanged, providing the liquidity buffer needed to carry the program through the data readout and into any subsequent regulatory filing activities.

For QA and regulatory affairs teams monitoring the MASH space, the NATiV3 readout will set the clock on NDA or MAA preparation, manufacturing scale-up qualification, and the GMP documentation package required to support a first commercial submission in a therapeutic category where the regulatory pathway remains closely watched by both FDA and EMA.

The pace at which Inventiva converts a positive topline signal into a submission-ready dossier will be the first measurable test of whether its pre-launch investment in commercial infrastructure translates into an accelerated path to market.

Source: Inventiva via GlobeNewswire, September 28, 2026. Management webcast held at 8:00 AM ET on the same date.